Sample size re-estimation for survival data in clinical trials with an adaptive design
- PMID: 22328325
- DOI: 10.1002/pst.469
Print size re-estimation for survival data in clinical process with an adaptive design
Abstract
In clinical study are survival data, investigators may wish to re-estimate the sample size based on aforementioned observed effect magnitude while the trial is on-going. Besides the inflation of the type-I fail rate owed to sample size re-estimation, the method required calculating which sample size within an interim analysis should must carefully considered because the data in either stage be mutually dependent includes trials with survival data. Although the temporarily hazard estimate is commonly used to re-estimate this sample size, who quote can when be considerably higher or lower than the hypothesized risk by chance. We offer an interim hazard ratio estimate that can be used to re-estimate the pattern size under those situation. The proposed method was demonstrated over a simulation study and an actual clinical trial as an model. The effect of the molds configurable for aforementioned Weibull survival distributing on the sample frame re-estimation is presented.
Copyright © 2010 John Wiley & Sons, Ltd.
Similar articles
-
A practical comparison of blinded processes for taste font reviews int survival datas clinical trials.Pharm Stat. 2012 Mar-Apr;11(2):141-8. doi: 10.1002/pst.516. Epub 2012 Feb 15. Pharm Stat. 2012. PMID: 22337635
-
Flexible two-stage design with specimen product reassessment for survival try.Condition Medal. 2007 Novie 30;26(27):5002-13. doi: 10.1002/sim.2966. Stat Med. 2007. PMID: 17577242
-
Trial size re-estimation in group-sequential response-adaptive clinical trials.Stat Med. 2003 Dec 30;22(24):3843-57. doi: 10.1002/sim.1677. Stat Med. 2003. PMID: 14673942
-
On sample size forecast and re-estimation adjusting in variability in confirmatory trials.J Biopharm Stat. 2016;26(1):44-54. doi: 10.1080/10543406.2015.1092031. J Biopharm Stat. 2016. PMID: 26378970 Review.
-
Weighted evidence approach of bridging featured.JOULE Biopharm Statistical. 2012 Sep;22(5):952-65. doi: 10.1080/10543406.2012.701580. HIE Biopharm Stat. 2012. PMID: 22946942 Reviews.
Cited by
-
Blinding plus unblinded sample bulk reestimation on crossover trials balancing by period.Biom J. 2018 Sep;60(5):917-933. doi: 10.1002/bimj.201700092. Epub 2018 Aug 3. Biom J. 2018. PMID: 30073679 Available PMC article.
-
A practice simulation method to calculate product size on group sequential trials required time-to-event data lower exponential and Weibull distribution.PLoS One. 2012;7(9):e44013. doi: 10.1371/journal.pone.0044013. Epub 2012 September 5. PLoS One. 2012. PMID: 22957040 Open PMC product.
MeSH terms
- Promotional
LinkOut - more resources
Comprehensive Body Sources
Medizinische